Sex Differences in Coronary Atheroma Regression After Intensive Lipid-Lowering Therapy Authors: Agam Bansal, Julie St. John, Rishi Puri, Stephen J. Nicholls, Steven E. Nissen, Leslie Cho Published: 2026 ABSTRACT BackgroundIntensive lipid-lowering therapy with high-intensity statins, with or without proprotein convertase subtilisin/kexin type 9 inhibitors, reduces coronary plaque burden. However, whether men and women experience similar atheroma regression and plaque compositional changes remains uncertain.ObjectivesThe objective of the study was to quantify sex-specific changes in percent atheroma volume (PAV), total atheroma volume (TAV), and plaque composition after intensive lipid-lowering, using pooled individual-participant data from four serial intravascular ultrasound trials.MethodsData from REVERSAL, ASTEROID, SATURN, and GLAGOV trials (N = 2,737; 1,987 men, 750 women) were analyzed centrally. Over a median follow-up of 20.7 months, annualized changes in PAV, TAV, and virtual histology components were compared using linear mixed-effects models adjusted for baseline plaque burden and trial.ResultsWomen were older with higher rates of hypertension and diabetes but presented with lower baseline PAV (mean: 34.5% vs 38.5%) and less extensive plaque composition abnormalities, even when normalized for plaque burden. Virtual histology analysis revealed women had lower baseline fibro-fatty volume (median: 13.7 vs 34.3 mm3), necrotic core volume (median: 7.7 vs 13.1 mm3), and higher fibrous content (mean: 41.5% vs 36.7%). Following treatment achieving similar low-density lipoprotein-cholesterol (LDL-C) (∼70 mg/dL), women showed greater regression in PAV (least-squares-mean: −0.25% vs −0.05%) and TAV, with similar plaque stabilization. Female sex independently predicted PAV regression, which was most pronounced in women achieving LDL-C <55 mg/dL.ConclusionsWomen undergoing clinically indicated procedures present with paradoxically less extensive atheroma and more favorable plaque composition despite higher cardiovascular risk burden. They experience greater coronary plaque regression than men after intensive lipid-lowering, especially when LDL-C is below 55 mg/dL, with similar plaque stabilization. Atherosclerotic cardiovascular disease remains the leading global cause of death; coronary artery disease (CAD) accounts for the greatest share of major adverse cardiovascular events (MACE).1 Intensive lipid lowering with statins reduces MACE chiefly by stabilizing and regressing coronary plaques.2,3 Intravascular ultrasound (IVUS) is the in vivo gold standard for quantifying atheroma burden and vessel dimensions,4 whereas virtual histology (VH) (IVUS-VH) provides detailed characterization of plaque composition including fibrous, fibro-fatty, necrotic core, and dense calcium components.5 Four landmark IVUS trials—REVERSAL,6 ASTEROID,7 SATURN8, and GLAGOV9—showed that high-intensity statin therapy (HIST), with or without proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition, induces plaque regression, especially when low-density lipoprotein-cholesterol (LDL-C) falls below 60 to 70 mg/dL.10,11 However, whether men and women experience similar atheroma regression and plaque compositional changes remains poorly understood. Despite the well-established benefit of LDL-C reduction, women are less likely than men to receive guideline-recommended HIST and less likely to attain LDL targets.12, 13, 14 Observational studies continue to show significant sex disparities in statin initiation and LDL-C goal achievement among high-risk populations.13,14 Subgroup analyses from earlier IVUS trials hinted that women might experience greater relative plaque regression, but those studies involved statin monotherapy and were limited by higher achieved LDL-C levels and lack of detailed plaque composition analysis.3,15 To address this knowledge gap, we performed an individual-participant pooled analysis of the four major IVUS trials—including combination statin + PCSK9 therapy and incorporating VH data from SATURN and GLAGOV—to: 1) quantify sex-specific atheroma regression; 2) characterize baseline sex differences in plaque composition; 3) assess plaque compositional responses to intensive lipid lowering; and 4) determine whether treatment effects differ at very low achieved LDL-C levels. Methods Study design and population This study is a patient-level, post hoc pooled analysis of four landmark randomized controlled trials: REVERSAL,6 ASTEROID,7 SATURN,8 and GLAGOV.9 Each trial evaluated the effects of intensive lipid-lowering therapy using serial IVUS imaging over an 18 to 24 month period. The trials enrolled patients with angiographically confirmed CAD and assessed changes in coronary plaque burden in response to statin monotherapy or combination therapy with a PCSK9 inhibitor. A total of 2,737 participants (1,987 men and 750 women) were included for the primary IVUS analysis. VH analysis was available for 414 participants (308 men and 106 women) from the SATURN and GLAGOV trials. All participants had at least 1 native coronary artery with >20% angiographic stenosis that had not undergone prior intervention and was not considered the infarct-related artery. This >20% angiographic stenosis requirement was an inclusion criterion defining the imaged target vessel rather than a threshold for exclusion; accordingly, no participants were excluded from the present pooled analysis on the basis of baseline stenosis grade. IVUS image acquisition and analysis IVUS imaging was performed using a 40- or 45-MHz catheter with automated pull back at 0.5 mm/s following administration of intracoronary nitroglycerin (200 μg). The same coronary segment was imaged at baseline and at follow-up using consistent anatomic landmarks. Core laboratory personnel, blinded to treatment allocation and sex, performed all analyses. Lumen and external elastic membrane (EEM) borders were manually traced at 1-mm intervals. Percent atheroma volume (PAV), the primary endpoint, was calculated as: PAV = (Σ [EEM area − lumen area] / ΣEEM area) × 100 Total atheroma volume (TAV) was normalized across participants by multiplying average plaque area by the median number of analyzed images. Virtual histology analysis IVUS-VH analysis was performed using validated spectral analysis of radiofrequency IVUS data in the SATURN and GLAGOV cohorts. Plaque components were classified into four categories: fibrous (green), fibro-fatty (yellow-green), necrotic core (red), and dense calcium (white). VH measurements included absolute volumes (mm3), normalized volumes (mm3), and percentage composition of each component. The ratio of necrotic core to dense calcium was calculated as a marker of plaque vulnerability. Biochemical measurements Fasting lipid profiles, apolipoproteins (apolipoprotein A1 [apoA1], apolipoprotein B [apoB]), and high-sensitivity C-reactive protein (CRP) were centrally measured using standardized assays. On-treatment values were calculated as the mean of at least two postbaseline assessments. Outcomes The primary outcome was the annualized change in PAV from baseline to follow-up. Secondary outcomes included changes in TAV and sex-by-lipid parameter interaction effects stratified by prespecified atherogenic thresholds: LDL-C <55 mg/dL and apoB <55 mg/dL. Statistical analysis Continuous baseline characteristics and plaque measures were compared between sexes using the Student’s t-test or Wilcoxon rank sum test, as appropriate based on data distribution, with mean ± SD or median (IQR) reported, respectively. Categorical baseline characteristics were compared using the chi-squared test with frequency and percent reported. The association of sex with primary and secondary change from baseline outcomes was assessed using linear mixed-effects models with trial set as a random effect and adjustment for each respective baseline IVUS measure. Least-squares mean (LS-mean) ± SE is reported. For the annualized change in PAV outcome, the LS-mean minus SE is plotted in figures to illustrate regression by sex. This analysis was also stratified by lipids using a cut point of 55 mg/dL with sex-by-lipid interactions being tested. Furthermore, men vs women were compared in subgroup analyses pertaining to diabetes, hypertension, smoking, and type of coronary syndrome with each sex-by-subgroup interaction tested here as well. A multivariable mixed-effects model was created to assess the effect of sex on annualized change in PAV while adjusting for trial, baseline PAV, and other significant variables. Baseline characteristics, baseline and concomitant medications, and baseline and change in lipid parameters were considered for the model. Bootstrap resampling was utilized for variable selection. Those variables showing up at least 20% of the time in the bootstrap resampling were kept and entered together into another mixed-effect model in order to form the final set of significant covariates. Β-coefficients with 95% CI are reported with continuous variables given per SD. All tests are 2-tailed with a 0.05 significance level. Statistical analysis was performed using SAS (version 9.4, SAS Institute Inc). Figures were generated in R (version 4.4.1, The R Foundation for Statistical Computing). This is a secondary analysis of deidentified, individual-participant data from four previously completed and published randomized trials (REVERSAL, ASTEROID, SATURN, and GLAGOV), each of which was approved by the institutional review board at every participating site with written informed consent obtained from all participants at the time of the original trials. Results Patient demographics and clinical characteristics The pooled cohort consisted of 2,737 patients, including 1,987 men (72.6%) and 750 women (27.4%). Women were older (59.8 ± 9.0 vs 57.4 ± 9.1 years; P < 0.001), had higher body mass index (30.1 ± 6.1 vs 29.2 ± 5.0 kg/m2; P < 0.001), and were more frequently hypertensive (85.5% vs 73.9%; P < 0.001) and diabetic (24.9% vs 16.9%; P < 0.001). Conversely, they were less likely to have a history of myocardial infarction (21.7% vs 33.5%; P < 0.001) or acute coronary syndrome (23.4% vs 31.6%; P < 0.001). Prior use of statin therapy was also less common in women (66.5% vs 72.7%; P = 0.002) (Table 1).Table 1Baseline Demographics, Clinical Characteristics, and Concomitant Medications of the Pooled Cohort, Stratified by SexTotal (N = 2,737)Male (n = 1,987)Female (n = 750)P ValueAge (y)58.1 ± 9.257.4 ± 9.159.8 ± 9.0<0.001BMI (kg/m2)29.4 ± 5.329.2 ± 5.030.1 ± 6.1<0.001History of MI829 (30.3)666 (33.5)163 (21.7)<0.001History of hypertension2,110 (77.1)1,469 (73.9)641 (85.5)<0.001Diabetes523 (19.1)336 (16.9)187 (24.9)<0.001Current smoker674 (28.2)497 (28.5)177 (27.4)0.59Acute coronary syndrome656 (29.4)513/1,625 (31.6)143 (23.4)<0.001Prior lipid-lowering therapy1,943 (71.0)1,444 (72.7)499 (66.5)0.002Concomitant medications Aspirin2,491 (91.0)1,817 (91.4)674 (89.9)0.20 Beta blockers2,092 (76.4)1,509 (75.9)583 (77.7)0.33 ACE inhibitors1,457 (53.2)1,083 (54.5)374 (49.9)0.03 ARB545 (19.9)344 (17.3)201 (26.8)<0.001 Nitrates483 (17.6)325 (16.4)158 (21.1)0.004Values are mean ± SD or n (%).ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; BMI = body mass index; MI = myocardial infarction. Table 1Baseline Demographics, Clinical Characteristics, and Concomitant Medications of the Pooled Cohort, Stratified by SexTotal (N = 2,737)Male (n = 1,987)Female (n = 750)P ValueAge (y)58.1 ± 9.257.4 ± 9.159.8 ± 9.0<0.001BMI (kg/m2)29.4 ± 5.329.2 ± 5.030.1 ± 6.1<0.001History of MI829 (30.3)666 (33.5)163 (21.7)<0.001History of hypertension2,110 (77.1)1,469 (73.9)641 (85.5)<0.001Diabetes523 (19.1)336 (16.9)187 (24.9)<0.001Current smoker674 (28.2)497 (28.5)177 (27.4)0.59Acute coronary syndrome656 (29.4)513/1,625 (31.6)143 (23.4)<0.001Prior lipid-lowering therapy1,943 (71.0)1,444 (72.7)499 (66.5)0.002Concomitant medications Aspirin2,491 (91.0)1,817 (91.4)674 (89.9)0.20 Beta blockers2,092 (76.4)1,509 (75.9)583 (77.7)0.33 ACE inhibitors1,457 (53.2)1,083 (54.5)374 (49.9)0.03 ARB545 (19.9)344 (17.3)201 (26.8)<0.001 Nitrates483 (17.6)325 (16.4)158 (21.1)0.004Values are mean ± SD or n (%).ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; BMI = body mass index; MI = myocardial infarction. Baseline Demographics, Clinical Characteristics, and Concomitant Medications of the Pooled Cohort, Stratified by Sex Values are mean ± SD or n (%). ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; BMI = body mass index; MI = myocardial infarction. Baseline and on-treatment lipid profiles At baseline, women had significantly higher LDL-C, high-density lipoprotein-cholesterol (HDL-C), apoA1, and CRP levels compared with men (Table 2). Both sexes achieved similar on-treatment LDL-C (∼70 mg/dL) and apoB (∼76 mg/dL) (Supplemental Table 1), but women experienced greater absolute reductions in LDL-C (mean: −50.7 vs −47.2 mg/dL; P = 0.025) and non-HDL-C (mean: −55.6 vs −51.4 mg/dL; P = 0.014) (Table 3). Despite similar statin intensity, women retained higher HDL-C and apoA1 levels at follow-up (P < 0.001 for both). On-treatment CRP also remained significantly elevated in women (median: 2.0 vs 1.2 mg/L; P < 0.001), suggestive of persistent low-grade inflammation. Detailed on-treatment biomarker data are provided in Supplemental Table 1.Table 2Baseline Lipid and Inflammatory Biomarker Profile of the Pooled Cohort, Stratified by SexTotal (N = 2,737)Male (n = 1,987)Female (n = 750)P ValueLDL-C (mg/dL)118.1 ± 35.0116.7 ± 33.9121.8 ± 37.40.001HDL-C (mg/dL)44.6 ± 11.642.6 ± 10.549.8 ± 12.7<0.001Non-HDL-C (mg/dL)148.9 ± 41.3147.3 ± 40.4153.3 ± 43.50.001Triglycerides (mg/dL)135 (97, 189)133 (96, 188)140 (101, 191)0.09hs-CRP (mg/L)1.8 (0.9, 3.9)1.7 (0.8, 3.5)2.3 (1.1, 5.4)<0.001Apolipoprotein A1 (mg/dL)133.9 ± 25.9129.7 ± 23.8145.2 ± 27.7<0.001Apolipoprotein B (mg/dL)109.4 ± 33.8108.6 ± 33.1111.6 ± 35.70.039Total cholesterol/HDL ratio4.6 ± 1.44.7 ± 1.44.3 ± 1.4<0.001Values are mean ± SD or median (IQR).HDL-C = high-density lipoprotein-cholesterol; hs-CRP = high-sensitivity C-reactive protein; LDL-C = low-density lipoprotein-cholesterol.Table 3Change in Average Follow-Up Lipid and Inflammatory Biomarkers From Baseline of the Pooled Cohort, Stratified by SexTotal (N = 2,737)Male (n = 1,987)Female (n = 750)P ValueLDL-C (mg/dL)−48.2 ± 35.5−47.2 ± 34.9−50.7 ± 36.80.025HDL-C (mg/dL)3.7 ± 7.13.7 ± 6.73.5 ± 7.90.42Non-HDL Cholesterol (mg/dL)−52.5 ± 40.0−51.4 ± 39.4−55.6 ± 41.30.014Triglycerides (mg/dL)−13.3 (−46.2, 14.4)−13.3 (−46.5, 14.5)−13.5 (−46.0, 14.3)0.47hs-CRP (mg/L)−0.2 (−1.3, 0.5)−0.2 (−1.2, 0.5)−0.2 (−1.4, 0.5)0.56Apolipoprotein A1 (mg/dL)11.7 ± 19.812.3 ± 19.310.3 ± 21.00.036Apolipoprotein B (mg/dL)−33.5 ± 27.7−33.0 ± 27.4−34.9 ± 28.40.11Total cholesterol/HDL ratio−1.4 ± 1.2−1.4 ± 1.2−1.3 ± 1.20.005Values are mean ± SD or median (IQR).Abbreviations as in Table 2. Table 2Baseline Lipid and Inflammatory Biomarker Profile of the Pooled Cohort, Stratified by SexTotal (N = 2,737)Male (n = 1,987)Female (n = 750)P ValueLDL-C (mg/dL)118.1 ± 35.0116.7 ± 33.9121.8 ± 37.40.001HDL-C (mg/dL)44.6 ± 11.642.6 ± 10.549.8 ± 12.7<0.001Non-HDL-C (mg/dL)148.9 ± 41.3147.3 ± 40.4153.3 ± 43.50.001Triglycerides (mg/dL)135 (97, 189)133 (96, 188)140 (101, 191)0.09hs-CRP (mg/L)1.8 (0.9, 3.9)1.7 (0.8, 3.5)2.3 (1.1, 5.4)<0.001Apolipoprotein A1 (mg/dL)133.9 ± 25.9129.7 ± 23.8145.2 ± 27.7<0.001Apolipoprotein B (mg/dL)109.4 ± 33.8108.6 ± 33.1111.6 ± 35.70.039Total cholesterol/HDL ratio4.6 ± 1.44.7 ± 1.44.3 ± 1.4<0.001Values are mean ± SD or median (IQR).HDL-C = high-density lipoprotein-cholesterol; hs-CRP = high-sensitivity C-reactive protein; LDL-C = low-density lipoprotein-cholesterol. Baseline Lipid and Inflammatory Biomarker Profile of the Pooled Cohort, Stratified by Sex Values are mean ± SD or median (IQR). HDL-C = high-density lipoprotein-cholesterol; hs-CRP = high-sensitivity C-reactive protein; LDL-C = low-density lipoprotein-cholesterol. Table 3Change in Average Follow-Up Lipid and Inflammatory Biomarkers From Baseline of the Pooled Cohort, Stratified by SexTotal (N = 2,737)Male (n = 1,987)Female (n = 750)P ValueLDL-C (mg/dL)−48.2 ± 35.5−47.2 ± 34.9−50.7 ± 36.80.025HDL-C (mg/dL)3.7 ± 7.13.7 ± 6.73.5 ± 7.90.42Non-HDL Cholesterol (mg/dL)−52.5 ± 40.0−51.4 ± 39.4−55.6 ± 41.30.014Triglycerides (mg/dL)−13.3 (−46.2, 14.4)−13.3 (−46.5, 14.5)−13.5 (−46.0, 14.3)0.47hs-CRP (mg/L)−0.2 (−1.3, 0.5)−0.2 (−1.2, 0.5)−0.2 (−1.4, 0.5)0.56Apolipoprotein A1 (mg/dL)11.7 ± 19.812.3 ± 19.310.3 ± 21.00.036Apolipoprotein B (mg/dL)−33.5 ± 27.7−33.0 ± 27.4−34.9 ± 28.40.11Total cholesterol/HDL ratio−1.4 ± 1.2−1.4 ± 1.2−1.3 ± 1.20.005Values are mean ± SD or median (IQR).Abbreviations as in Table 2. Change in Average Follow-Up Lipid and Inflammatory Biomarkers From Baseline of the Pooled Cohort, Stratified by Sex Values are mean ± SD or median (IQR). Abbreviations as in Table 2. Sex differences in baseline atheroma burden Baseline IVUS imaging revealed that women had significantly lower PAV (PAV: 34.5% ± 9.0% vs 38.5% ± 8.8%; P < 0.001) and TAV (TAV: 157.9 ± 70.7 mm3 vs 200.5 ± 83.3 mm3; P < 0.001). These differences extended to normalized vessel and lumen volumes, indicating lower plaque and vessel burden in women at study entry (Table 4).Table 4Baseline Intravascular Ultrasound Measurements of Coronary Atheroma and Vessel Dimensions of the Pooled Cohort, Stratified by SexTotal (N = 2,737)Male (n = 1,987)Female (n = 750)P ValuePercent atheroma volume (%)37.4 ± 9.138.5 ± 8.834.5 ± 9.0<0.001Total atheroma volume (mm3)188.8 ± 82.2200.5 ± 83.3157.9 ± 70.7<0.001Vessel volume (mm3)499.5 ± 168.6517.5 ± 174.2451.7 ± 142.5<0.001Lumen volume (mm3)310.6 ± 110.1317.0 ± 114.7293.7 ± 95.0<0.001Values are mean ± SD. Table 4Baseline Intravascular Ultrasound Measurements of Coronary Atheroma and Vessel Dimensions of the Pooled Cohort, Stratified by SexTotal (N = 2,737)Male (n = 1,987)Female (n = 750)P ValuePercent atheroma volume (%)37.4 ± 9.138.5 ± 8.834.5 ± 9.0<0.001Total atheroma volume (mm3)188.8 ± 82.2200.5 ± 83.3157.9 ± 70.7<0.001Vessel volume (mm3)499.5 ± 168.6517.5 ± 174.2451.7 ± 142.5<0.001Lumen volume (mm3)310.6 ± 110.1317.0 ± 114.7293.7 ± 95.0<0.001Values are mean ± SD. Baseline Intravascular Ultrasound Measurements of Coronary Atheroma and Vessel Dimensions of the Pooled Cohort, Stratified by Sex Values are mean ± SD. VH analysis from a subset of SATURN and GLAGOV participants (n = 414) revealed notable sex differences in plaque composition (Table 5). Despite presenting for clinically indicated procedures, women had significantly less extensive plaque composition abnormalities, even when normalized for plaque burden compared to men: fibro-fatty volume (median [IQR]: 13.7 [5.8, 29.7] mm3 vs 34.3 [16.1, 62.4] mm3; P < 0.001), necrotic core volume (median [IQR]: 7.7 [2.1, 15.4] mm3 vs 13.1 [5.9, 22.3] mm3; P < 0.001), and dense calcium volume (median [IQR]: 1.7 [0.4, 5.5] mm3 vs 3.1 [0.7, 7.4] mm3; P = 0.003). Conversely, women had a higher percentage of fibrous tissue (mean ± SD: 41.5 ± 13.1% vs 36.7 ± 11.5%; P = 0.001), indicating more stable plaque composition.Table 5Baseline Virtual Histology Plaque Composition Analysis From SATURN and GLAGOV Cohorts, Stratified by SexTotal (N = 414)Male (n = 308)Female (n = 106)P ValueStudy0.36 SATURN83 (20)65 (21.1)18 (17.0) GLAGOV331 (80)243 (78.9)88 (83.0)Length (mm)48.8 ± 15.948.6 ± 16.049.5 ± 15.50.61Fibrofatty volume (mm3)27.0 (12.5, 57.6)34.3 (16.1, 62.4)13.7 (5.8, 29.7)<0.001Normalized fibro-fatty volume (mm3)20.8 (9.0, 43.0)25.6 (13.1, 47.3)10.8 (4.1, 21.0)<0.001Fibrofatty percent based on volume (%)40.7 ± 16.142.3 ± 15.835.7 ± 16.0<0.001Fibrous volume (mm3)26.9 (13.7, 46.5)30.2 (16.2, 48.6)16.8 (6.8, 35.4)<0.001Normalized fibrous volume (mm3)19.7 (10.3, 32.8)22.5 (12.3, 36.6)13.5 (5.7, 23.8)<0.001Fibrous percent based on volume (%)37.9 ± 12.136.7 ± 11.541.5 ± 13.10.001Necrotic core volume (mm3)11.1 (4.8, 20.8)13.1 (5.9, 22.3)7.7 (2.1, 15.4)<0.001Normalized necrotic core volume (mm3)8.4 (3.7, 15.7)10.1 (4.6, 16.9)5.3 (1.6, 11.1)<0.001Necrotic core percent based on volume (%)16.1 ± 7.215.7 ± 7.017.1 ± 7.80.09Dense calcium volume (mm3)2.5 (0.6, 6.7)3.1 (0.7, 7.4)1.7 (0.4, 5.5)0.003Dense calcium percent based on volume (%)3.7 (1.4, 8.1)3.6 (1.4, 8.0)4.5 (1.4, 8.4)0.54Ratio of necrotic core to dense calcium3.8 (2.3, 7.5)3.9 (2.3, 7.5)3.7 (2.3, 7.3)0.73Values are n (%), mean ± SD, or median (IQR). Table 5Baseline Virtual Histology Plaque Composition Analysis From SATURN and GLAGOV Cohorts, Stratified by SexTotal (N = 414)Male (n = 308)Female (n = 106)P ValueStudy0.36 SATURN83 (20)65 (21.1)18 (17.0) GLAGOV331 (80)243 (78.9)88 (83.0)Length (mm)48.8 ± 15.948.6 ± 16.049.5 ± 15.50.61Fibrofatty volume (mm3)27.0 (12.5, 57.6)34.3 (16.1, 62.4)13.7 (5.8, 29.7)<0.001Normalized fibro-fatty volume (mm3)20.8 (9.0, 43.0)25.6 (13.1, 47.3)10.8 (4.1, 21.0)<0.001Fibrofatty percent based on volume (%)40.7 ± 16.142.3 ± 15.835.7 ± 16.0<0.001Fibrous volume (mm3)26.9 (13.7, 46.5)30.2 (16.2, 48.6)16.8 (6.8, 35.4)<0.001Normalized fibrous volume (mm3)19.7 (10.3, 32.8)22.5 (12.3, 36.6)13.5 (5.7, 23.8)<0.001Fibrous percent based on volume (%)37.9 ± 12.136.7 ± 11.541.5 ± 13.10.001Necrotic core volume (mm3)11.1 (4.8, 20.8)13.1 (5.9, 22.3)7.7 (2.1, 15.4)<0.001Normalized necrotic core volume (mm3)8.4 (3.7, 15.7)10.1 (4.6, 16.9)5.3 (1.6, 11.1)<0.001Necrotic core percent based on volume (%)16.1 ± 7.215.7 ± 7.017.1 ± 7.80.09Dense calcium volume (mm3)2.5 (0.6, 6.7)3.1 (0.7, 7.4)1.7 (0.4, 5.5)0.003Dense calcium percent based on volume (%)3.7 (1.4, 8.1)3.6 (1.4, 8.0)4.5 (1.4, 8.4)0.54Ratio of necrotic core to dense calcium3.8 (2.3, 7.5)3.9 (2.3, 7.5)3.7 (2.3, 7.3)0.73Values are n (%), mean ± SD, or median (IQR). Baseline Virtual Histology Plaque Composition Analysis From SATURN and GLAGOV Cohorts, Stratified by Sex Values are n (%), mean ± SD, or median (IQR). Atheroma regression following lipid-lowering therapy After 18 to 24 months of therapy and while adjusting for respective baseline measures and trial, women demonstrated significantly greater regression in both PAV (LS-mean ± SE: −0.25 ± 0.32% vs −0.05 ± 0.32%; P = 0.005) and TAV (LS-mean ± SE: −3.43 ± 1.86 mm3 vs −2.50 ± 1.84 mm3; P = 0.047) (Table 7 and Figure 1). No statistically significant sex differences were observed in changes in EEM or lumen volume.Table 7One-Year Changes in Intravascular Ultrasound–Derived Coronary Parameters Following Intensive Lipid-Lowering Therapy of the Pooled Cohort, Stratified by SexTotal (N = 2,737)Male (n = 1,987)Female (n = 750)P ValuePercent atheroma volume (%)−0.11 ± 0.32−0.05 ± 0.32−0.25 ± 0.320.005Total atheroma volume (mm3)−2.77 ± 1.84−2.50 ± 1.84−3.43 ± 1.860.047Vessel volume (mm3)−5.44 ± 1.96−5.32 ± 1.98−5.75 ± 2.100.68Lumen volume (mm3)−2.66 ± 1.81−2.60 ± 1.82−2.83 ± 1.900.79Least-squares mean ± SE are reported, adjusting for the respective baseline intravascular ultrasound measure and trial. For each outcome, estimates for men, women, and their difference are derived from a single joint model including sex as a fixed effect; the P value tests the sex effect.Figure 1Annualized Change in Percent Atheroma Volume by SexLeast-squares means minus SE of annualized change in PAV in men (blue) vs women (red), adjusting for baseline PAV and trial. Women exhibited significantly greater plaque regression (P = 0.005). PAV = percent atheroma volume. Table 7One-Year Changes in Intravascular Ultrasound–Derived Coronary Parameters Following Intensive Lipid-Lowering Therapy of the Pooled Cohort, Stratified by SexTotal (N = 2,737)Male (n = 1,987)Female (n = 750)P ValuePercent atheroma volume (%)−0.11 ± 0.32−0.05 ± 0.32−0.25 ± 0.320.005Total atheroma volume (mm3)−2.77 ± 1.84−2.50 ± 1.84−3.43 ± 1.860.047Vessel volume (mm3)−5.44 ± 1.96−5.32 ± 1.98−5.75 ± 2.100.68Lumen volume (mm3)−2.66 ± 1.81−2.60 ± 1.82−2.83 ± 1.900.79Least-squares mean ± SE are reported, adjusting for the respective baseline intravascular ultrasound measure and trial. For each outcome, estimates for men, women, and their difference are derived from a single joint model including sex as a fixed effect; the P value tests the sex effect. One-Year Changes in Intravascular Ultrasound–Derived Coronary Parameters Following Intensive Lipid-Lowering Therapy of the Pooled Cohort, Stratified by Sex Least-squares mean ± SE are reported, adjusting for the respective baseline intravascular ultrasound measure and trial. For each outcome, estimates for men, women, and their difference are derived from a single joint model including sex as a fixed effect; the P value tests the sex effect. Annualized Change in Percent Atheroma Volume by Sex Least-squares means minus SE of annualized change in PAV in men (blue) vs women (red), adjusting for baseline PAV and trial. Women exhibited significantly greater plaque regression (P = 0.005). PAV = percent atheroma volume. Virtual histology changes and plaque stabilization VH analysis demonstrated that both men and women showed similar patterns of plaque compositional changes consistent with stabilization. Both sexes experienced similar reduction in fibro-fatty volume (median [IQR] in men: −3.9 [−14.5, 1.4] mm3; women: −1.2 [−8.0, 1.2] mm3; P = 0.15), reduction in fibrous volume (median [IQR] in men: −2.6 [−8.9, 1.9] mm3; women: −3.1 [−9.9, 0.2] mm3; P = 0.30), minimal change in necrotic core volume (median [IQR] in men: −0.2 [−4.2, 2.7] mm3; women: −0.1 [−3.6, 0.8] mm3; P = 0.32), and modest increase in dense calcium volume (median [IQR] in men: 0.3 [−0.6, 2.4] mm3; women: 0.1 [−0.2, 1.4] mm3; P = 0.66). The necrotic core-to-dense calcium ratio, a marker of plaque vulnerability, was similar between sexes at both baseline (median 3.9 vs 3.7; P = 0.73) and follow-up (3.1 vs 2.8; P = 0.40), with no significant sex difference in its change over time, consistent with comparable plaque stabilization in men and women (Table 6).Table 6Follow-Up Virtual Histology Plaque Composition Analysis From SATURN and GLAGOV Cohorts, Stratified by SexTotal (N = 414)Male (n = 308)Female (n = 106)P ValueLength (mm)47.7 ± 15.947.8 ± 16.247.6 ± 15.10.93Fibro-fatty volume (mm3)21.1 (8.7, 44.1)26.9 (11.5, 49.3)10.4 (3.7, 21.5)<0.001Normalized fibro-fatty volume (mm3)16.0 (6.4, 34.0)20.8 (8.5, 40.1)8.7 (2.6, 16.7)<0.001Fibro-fatty percent based on volume (%)38.7 ± 17.240.3 ± 17.233.8 ± 16.50.001Fibrous volume (mm3)22.7 (10.6, 38.9)26.6 (12.4, 41.2)15.0 (5.8, 24.4)<0.001Normalized fibrous volume (mm3)17.1 (8.2, 29.6)19.9 (9.6, 32.0)11.0 (5.3, 18.5)<0.001Fibrous percent based on volume (%)37.2 ± 12.136.1 ± 11.540.5 ± 13.20.001Necrotic core volume (mm3)10.1 (3.7, 19.8)12.1 (4.7, 21.6)5.8 (2.1, 12.4)<0.001Normalized necrotic core volume (mm3)7.7 (3.3, 15.1)8.8 (4.2, 16.2)4.7 (1.6, 9.9)<0.001Necrotic core percent based on volume (%)17.1 ± 8.116.9 ± 8.117.6 ± 7.80.46Dense calcium volume (mm3)3.1 (0.8, 8.1)3.7 (1.0, 9.4)2.2 (0.5, 5.4)0.002Dense calcium percent based on volume (%)5.0 (2.1, 10.7)4.9 (2.1, 10.4)6.2 (2.0, 12.2)0.29Ratio of necrotic core to dense calcium3.0 (1.9, 5.0)3.1 (2.0, 5.0)2.8 (1.8, 4.8)0.40Values are mean ± SD or median (IQR). Table 6Follow-Up Virtual Histology Plaque Composition Analysis From SATURN and GLAGOV Cohorts, Stratified by SexTotal (N = 414)Male (n = 308)Female (n = 106)P ValueLength (mm)47.7 ± 15.947.8 ± 16.247.6 ± 15.10.93Fibro-fatty volume (mm3)21.1 (8.7, 44.1)26.9 (11.5, 49.3)10.4 (3.7, 21.5)<0.001Normalized fibro-fatty volume (mm3)16.0 (6.4, 34.0)20.8 (8.5, 40.1)8.7 (2.6, 16.7)<0.001Fibro-fatty percent based on volume (%)38.7 ± 17.240.3 ± 17.233.8 ± 16.50.001Fibrous volume (mm3)22.7 (10.6, 38.9)26.6 (12.4, 41.2)15.0 (5.8, 24.4)<0.001Normalized fibrous volume (mm3)17.1 (8.2, 29.6)19.9 (9.6, 32.0)11.0 (5.3, 18.5)<0.001Fibrous percent based on volume (%)37.2 ± 12.136.1 ± 11.540.5 ± 13.20.001Necrotic core volume (mm3)10.1 (3.7, 19.8)12.1 (4.7, 21.6)5.8 (2.1, 12.4)<0.001Normalized necrotic core volume (mm3)7.7 (3.3, 15.1)8.8 (4.2, 16.2)4.7 (1.6, 9.9)<0.001Necrotic core percent based on volume (%)17.1 ± 8.116.9 ± 8.117.6 ± 7.80.46Dense calcium volume (mm3)3.1 (0.8, 8.1)3.7 (1.0, 9.4)2.2 (0.5, 5.4)0.002Dense calcium percent based on volume (%)5.0 (2.1, 10.7)4.9 (2.1, 10.4)6.2 (2.0, 12.2)0.29Ratio of necrotic core to dense calcium3.0 (1.9, 5.0)3.1 (2.0, 5.0)2.8 (1.8, 4.8)0.40Values are mean ± SD or median (IQR). Follow-Up Virtual Histology Plaque Composition Analysis From SATURN and GLAGOV Cohorts, Stratified by Sex Values are mean ± SD or median (IQR). Independent predictors of atheroma regression In a multivariable model adjusted for baseline PAV and trial, female sex was independently associated with greater PAV regression (β = −0.24; 95% CI: −0.38 to −0.10; P < 0.001). Other independent predictors included younger age, lower baseline apoB, greater reductions in LDL-C, and bigger increase in HDL-C. Baseline PAV showed a strong inverse association with regression magnitude (β = −0.48 per SD; P < 0.001) (Supplemental Table 2). Subgroup analyses Sex-based differences in plaque regression were consistent across subgroups stratified by diabetes, hypertension, smoking, and type of coronary syndrome. Women exhibited significantly greater regression within each diabetes strata, each hypertension strata, the nonsmoking strata, and the stable coronary syndrome strata. For patients without hypertension, women experienced markedly greater regression (LS-mean ± SE: −0.51% ± 0.36% vs −0.10% ± 0.33%; P = 0.019). For those with stable coronary syndrome, women again showed markedly greater regression (LS-mean ± SE: −0.58% ± 0.13% vs −0.29% ± 0.12%; P < 0.001). There were no significant sex-by-subgroup interactions for the diabetes, hypertension, and smoking stratum. There was a significant interaction between sex and type of coronary syndrome (P = 0.034) (Supplemental Table 3). Because one-quarter of the cohort were women with diabetes and plaque phenotype is known to differ by sex in diabetes, we examined the diabetic subgroup in detail (Supplemental Table 4). Among 523 diabetic patients (336 men, 187 women), women had lower baseline PAV (mean 37.1% vs 40.5%; P < 0.001) and, on VH (n = 76; 54 men, 22 women), lower baseline fibro-fatty volume (median 21.3 vs 50.1 mm3; P = 0.010) with a higher fibrous percentage (40.3% vs 34.8%; P = 0.037), mirroring the overall cohort. Following intensive lipid-lowering, diabetic women again showed significantly greater PAV regression than diabetic men (LS-mean −0.24% vs +0.11%; difference −0.35%; 95% CI: −0.65% to −0.06%; P = 0.018), whereas on-treatment changes in virtual-histology components were broadly comparable between sexes (all P > 0.05 except a modestly greater reduction in fibro-fatty volume in men; P = 0.044). These exploratory findings, limited by the small number of women with virtual-histology data in the diabetic subgroup, are hypothesis-generating and concordant with the primary analysis. Achieved LDL-C and apoB thresholds Regression analysis stratified by achieved lipoprotein levels showed that women experienced greater PAV regression in general. A similar proportion of each sex achieved an average follow-up LDL-C <55 mg/dL (women, 161/750 [21.5%]; men, 417/1,987 [21.0%]), indicating that the greater regression observed in women was not driven by a higher proportion of women reaching the very-low LDL-C threshold. This effect was most pronounced at LDL-C <55 mg/dL (LS-mean: −0.65% vs −0.24%; P < 0.001), with a statistically significant sex-by-LDL-C interaction (P = 0.034), suggesting women benefit more from intensive lipid-lowering (Figure 2, Central Illustration). A similar trend was observed for apoB <55 mg/dL (LS-mean: −0.60% vs −0.29%; P = 0.038), although the sex-by-apoB interaction was not statistically significant (P = 0.43) (Supplemental Figure 1).Figure 2Impact of Achieved Low-Density Lipoprotein Cholesterol on Sex-Specific Plaque RegressionLeast-squares means minus SE of annualized change in percent atheroma volume (PAV) in men (blue) and women (red), adjusting for baseline PAV and trial, and stratified by achieved on-treatment LDL-C <55 mg/dL vs ≥55 mg/dL. Women exhibit markedly greater regression when achieved LDL-C <55 mg/dL (P < 0.001). Sex-by-LDL-C interaction is significant (P = 0.034). LDL-C = low-density lipoprotein cholesterol.Central IllustrationSex Differences in Coronary Atheroma RegressionWomen demonstrate robust coronary plaque regression after intensive lipid-lowering therapy for secondary prevention of coronary artery disease, particularly when achieved LDL-C is below 55 mg/dL, with similar responsiveness in plaque stabilization. LDL-C = low-density lipoprotein cholesterol; PAV = percent atheroma volume. Impact of Achieved Low-Density Lipoprotein Cholesterol on Sex-Specific Plaque Regression Least-squares means minus SE of annualized change in percent atheroma volume (PAV) in men (blue) and women (red), adjusting for baseline PAV and trial, and stratified by achieved on-treatment LDL-C <55 mg/dL vs ≥55 mg/dL. Women exhibit markedly greater regression when achieved LDL-C <55 mg/dL (P < 0.001). Sex-by-LDL-C interaction is significant (P = 0.034). LDL-C = low-density lipoprotein cholesterol. Sex Differences in Coronary Atheroma Regression Women demonstrate robust coronary plaque regression after intensive lipid-lowering therapy for secondary prevention of coronary artery disease, particularly when achieved LDL-C is below 55 mg/dL, with similar responsiveness in plaque stabilization. LDL-C = low-density lipoprotein cholesterol; PAV = percent atheroma volume. Discussion In this individual-level pooled analysis of four landmark serial IVUS trials—REVERSAL,5 ASTEROID,6 SATURN,7 and GLAGOV8—enhanced by VH analysis from SATURN and GLAGOV, we found that women with established CAD exhibit significantly greater regression of atheroma burden than men following intensive lipid-lowering therapy. Despite higher prevalence of traditional cardiovascular risk factors, women presented with significantly lower baseline PAV and TAV, yet experienced nearly fivefold greater absolute PAV reduction. This finding persisted after rigorous multivariable adjustment, establishing female sex as an independent predictor of plaque regression.3,16,17 These results offer compelling evidence that biologic sex influences both the baseline atherosclerotic disease phenotype and the vascular response to lipid-lowering therapy, challenging long-standing assumptions that women are less likely to benefit from secondary prevention strategies18, 19, 20 and providing mechanistic insight into how intensive lipid-lowering may exert greater atheroprotective effects in women.11, 12, 13 Our baseline observations are consistent with a substantial body of coronary computed tomography angiography (CTA) literature. Prior CTA studies have established that, compared with men, women have lower overall coronary plaque burden, lower stenosis severity, and a plaque phenotype characterized by less calcified and less lipid-rich (non-calcified) plaque, as well as higher rates of plaque erosion, with accelerated plaque progression following menopause.21,22 The cross-sectional sex differences we observed at baseline are therefore confirmatory of this established work. The principal novel contribution of the present analysis is not the baseline phenotype but the longitudinal, treatment-response finding: the demonstration that women experience significantly greater atheroma regression than men following intensive lipid-lowering therapy. The incorporation of VH data provides additional, exploratory insight into sex-specific differences in coronary plaque composition, revealing 2 observations that complement the volumetric findings. First, the baseline paradox: despite presenting for clinically indicated catheterization procedures and having higher rates of hypertension (85.5% vs 73.9%) and diabetes (24.9% vs 16.9%), women demonstrated markedly less extensive plaque composition abnormalities, even when normalized for plaque burden. Women had approximately 60% lower median fibro-fatty volume (13.7 vs 34.3 mm3) and 41% lower median necrotic core volume (7.7 vs 13.1 mm3) compared to men, while maintaining a higher mean proportion of stabilizing fibrous tissue (41.5% vs 36.7%). This suggests that women reach the threshold for clinically indicated procedures with less extensive atherosclerotic burden, potentially reflecting different pathophysiologic mechanisms or clinical presentation patterns. Consistent with the coronary CTA literature, women also had lower baseline dense-calcium volume than men (median 1.7 vs 3.1 mm3; P = 0.003). Calcium was quantified as the dense-calcium component on VH and contributes to total atheroma on grayscale IVUS; in both cases it was retained in the PAV and TAV measurements, which quantify TAV irrespective of composition. This handling helps explain an apparent paradox—that women, despite presenting with less lipid-laden plaque, nevertheless demonstrated greater atheroma regression. Women's lower baseline necrotic-core and calcium content is consistent with a less advanced, more fibrous, and more biologically modifiable substrate, whereas men's larger necrotic cores and greater calcification represent more advanced, organized lesions that are comparatively "fixed" and less amenable to volumetric regression—plaque that may, in effect, be too far along to regress. Differences in calcified-plaque burden are therefore unlikely to have spuriously generated the observed sex difference in regression; rather, they point to a more modifiable disease substrate in women. Second, this suggests preserved therapeutic responsiveness. Despite these baseline differences, women demonstrated similar responsiveness to intensive lipid-lowering in terms of plaque stabilization markers. Both sexes showed comparable reductions in fibro-fatty and fibrous volumes, with minimal changes in necrotic core content and modest increases in calcification—patterns consistent with plaque stabilization. One of the most notable findings is the differential regression response at lower achieved LDL-C levels. Women demonstrated significantly greater plaque regression with the largest difference when achieving LDL-C levels below 55 mg/dL—a threshold now widely endorsed by European Society of Cardiology and American College of Cardiology/American Heart Association guidelines.9,10 At this level, women exhibited more than double the reduction in PAV compared with men, with a significant sex-by-LDL-C interaction. A similar trend, aside from a significant interaction, was observed for apoB, highlighting potentially sex-modulated sensitivity to atherogenic lipoprotein lowering.18 Several biologically plausible mechanisms may explain the enhanced regression observed in women. Women maintained significantly higher HDL-C and apoA1 levels both at baseline and after therapy.23,24 Beyond quantitative differences, HDL particles in women may possess superior functional properties, such as greater cholesterol efflux capacity and antioxidant potential.23,25 Estrogen has been shown to upregulate adenosine triphosphate–binding cassette transporters (eg, ABCA1 and ABCG1), enhancing cholesterol efflux from macrophages and reducing foam cell formation.26,27 The VH findings support the concept that plaque morphology itself may dictate regression potential, as women's baseline predominance of fibrous tissue with lower lipid content creates a more favorable substrate for volumetric reduction upon aggressive lipid lowering. Prior studies have shown that women are more likely to have fibrous, homogeneous plaques with less calcification and smaller lipid cores,28,29 features more amenable to volumetric reduction. Men tend to harbor more fibroatheromatous and calcified lesions, which may be less responsive to regression even when atherogenic lipoproteins are aggressively reduced.30 In addition, women may exhibit greater regulatory T-cell activity and reduced inflammasome activation, creating a more anti-inflammatory vascular milieu.31,32 Although on-treatment CRP levels remained higher in women, this may reflect a resolving inflammatory response in lipid-rich plaques undergoing remodeling.33 The inclusion of the GLAGOV trial, which evaluated PCSK9 inhibitor evolocumab addition to statin therapy,8 allowed assessment of very low LDL-C effects. Among women achieving LDL-C levels of 20 to 40 mg/dL, the magnitude of plaque regression supports the notion that "lower is better" may be particularly relevant in women.34,35 These findings should reinvigorate efforts to ensure that high-risk female patients receive not only high-intensity statins but also nonstatin lipid-lowering therapies—such as ezetimibe, PCSK9 inhibitors, or emerging agents like inclisiran or ANGPTL3 inhibitors36,37—when targets are not met. Multiple registry analyses have demonstrated that women with CAD are significantly less likely to receive guideline-recommended lipid-lowering therapy and achieve LDL-C goals.11, 12, 13,33 The data presented here suggest that failing to treat women as intensively may mean missing substantial opportunities to reduce atheroma burden and future cardiovascular risk. The clinical inertia contributing to undertreatment must be addressed through education, performance metrics, and inclusion of sex-specific recommendations in clinical guidelines.9,10,35 From a methodological perspective, this pooled analysis offers several advantages. The harmonized data from four large randomized controlled trials5, 6, 7, 8 with core-lab analyzed serial IVUS imaging yielded a robust data set with sufficient power to detect moderate effect sizes. The inclusion of VH data from SATURN and GLAGOV provided unique insights into plaque composition previously unavailable in sex-specific analyses. Linear mixed-effects models with trial as a random effect account for potential heterogeneity between studies, enhancing internal validity.38 Study limitations Several limitations merit discussion. First, this is a retrospective analysis of prospective trials, remaining hypothesis-generating.3 Although multivariable analyses adjust for known confounders, residual confounding cannot be excluded.3,17 Second, women comprised only 27% of the overall cohort, reflecting their under-representation in clinical trials.18,19,33 Although this limited power for certain subgroup analyses, the consistency of findings across all trials enhances credibility.18, 19, 20 Third, our primary endpoint was annualized change in PAV, a surrogate for clinical outcomes.37 Although PAV regression has been correlated with lower rates of MACE in prior studies, including SATURN and GLAGOV,7,8,39 our analysis did not assess clinical endpoints directly. Prospective outcome trials stratified by sex and incorporating plaque imaging endpoints are needed.17,40 We also lacked data on menopausal status, hormone replacement therapy use, or sex hormone levels, all of which could influence lipid metabolism and atherosclerotic biology.24,25,41 Future studies incorporating hormonal profiling would offer valuable insights into the interaction between hormonal milieu and therapeutic response.41,42 In addition, although IVUS-VH provides detailed plaque composition analysis, complementary imaging with optical coherence tomography or near-infrared spectroscopy may further elucidate sex differences in plaque composition and vulnerability.27,43,44 Quantitative coronary angiographic stenosis severity was not uniformly available across the four contributing trials, with complete percent-diameter-stenosis data available only for the smaller REVERSAL and ASTEROID cohorts; a reliable pooled estimate of average stenosis therefore could not be reported, and lesion-level stenosis-stratified analyses were not feasible. Finally, inferences regarding plaque vulnerability should be made cautiously, as IVUS-VH has well-recognized limitations in tissue characterization—including unreliable quantification of necrotic core and difficulty distinguishing calcified from fibrotic and other low-echo components—and is not used in routine clinical practice; the necrotic core–to–dense calcium ratio should therefore be regarded as an exploratory surrogate rather than a validated measure of vulnerability.PerspectivesCOMPETENCY IN MEDICAL KNOWLEDGE: HIST promotes coronary-plaque regression. Women receive less guideline-directed lipid-lowering therapy and are less likely to be under control. Limited data exist on sex differences in plaque composition and response to therapy.TRANSLATIONAL OUTLOOK: In a pooled IVUS cohort (n = 2,737), women showed 5× greater overall PAV regression than men (−0.25% vs −0.05%). VH analysis revealed women present with less extensive plaque burden and more favorable composition despite higher risk profiles. Women had significantly lower fibro-fatty and necrotic core volumes but similar responsiveness to plaque stabilization therapy. The sex advantage was largest for those achieving LDL-C <55 mg/dL. Clinical implication: Treat LDL-C (or apoB) to very-low targets and escalate therapy early in women. COMPETENCY IN MEDICAL KNOWLEDGE: HIST promotes coronary-plaque regression. Women receive less guideline-directed lipid-lowering therapy and are less likely to be under control. Limited data exist on sex differences in plaque composition and response to therapy. TRANSLATIONAL OUTLOOK: In a pooled IVUS cohort (n = 2,737), women showed 5× greater overall PAV regression than men (−0.25% vs −0.05%). VH analysis revealed women present with less extensive plaque burden and more favorable composition despite higher risk profiles. Women had significantly lower fibro-fatty and necrotic core volumes but similar responsiveness to plaque stabilization therapy. The sex advantage was largest for those achieving LDL-C <55 mg/dL. Clinical implication: Treat LDL-C (or apoB) to very-low targets and escalate therapy early in women. Conclusions This study demonstrates that women with CAD present a paradoxical clinical phenotype. Despite higher cardiovascular risk factor burden, they undergo clinically indicated procedures with significantly less extensive atheroma burden and more favorable plaque composition than men. Following intensive lipid-lowering therapy, women experience significantly greater atheroma regression while maintaining similar responsiveness in plaque stabilization markers, particularly when LDL-C is reduced below 55 mg/dL.9,10,34 These findings highlight the importance of adopting an aggressive, target-driven approach to lipid management in female patients and challenging the longstanding underappreciation of therapeutic efficacy in women.3,18 The VH insights provide a mechanistic framework for understanding these sex differences and support the concept that women may achieve greater therapeutic benefit from intensive lipid-lowering strategies. In an era of precision medicine, acknowledging sex-specific responses to therapy is paramount.17,18 Future clinical trials should prioritize equitable enrollment and explore mechanisms underlying differential treatment responses by sex.19,39,41 Moving forward, a more tailored approach to lipid management—guided by biologic sex, baseline plaque burden and composition, and achievable lipid targets—has the potential to transform secondary prevention and promote cardiovascular equity. Funding support and author disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.